Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for alleged misrepresentations regarding its capital allocation priorities and risks associated with its product Nexplanon during the class period from November 3, 2022, to April 30, 2025 [1][3][4] Company Overview - Organon & Co. is a healthcare company based in Jersey City, NJ, focusing on women's health [2] - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2] Lawsuit Details - The lawsuit claims that despite increasing debt from the Dermavant acquisition, Organon assured investors it would maintain its dividend as its "1 capital allocation priority" [3] - It is alleged that after the acquisition, Organon shifted its capital allocation focus towards reducing debt rather than maintaining dividends [3] - The lawsuit also states that Organon failed to disclose the heightened risk of loss of exclusivity and price erosion related to its product Nexplanon [4]

PHILADELPHIA, July 17, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC, a Philadelphia-based law firm focused on investor protection, is investigating claims against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket Pharmaceuticals” or the “Company”) for potential violations of federal securities laws. A class action has been filed over allegations that the Company concealed safety concerns tied to its RP-A501 trial, leading to steep investor losses. Rocket Pharmaceuticals is headquartered in Cranbury, New J ...

PHILADELPHIA, July 16, 2025 /PRNewswire/ -- Berger Montague announces a securities fraud investigation into Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) concerning potential violations of the Securities Exchange Act of 1934. The inquiry focuses on whether investors were misled about the Company's regulatory compliance and business operations.Following Novo Nordisk's termination of its collaboration with Hims & Hers on June 23, 2025, the Company's stock dropped more than 34%. A class ...

Core Viewpoint - Hims & Hers Health Inc. is under investigation for potential securities fraud following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and selling unapproved products [2][3] Group 1: Company Actions and Allegations - Hims & Hers is accused of making materially false or misleading statements regarding its GLP-1 offerings and the partnership with Novo Nordisk during the class period from April 29, 2025, to June 22, 2025 [3] - The termination of the partnership with Novo Nordisk led to a significant decline in Hims & Hers' stock price, dropping over 34% in intraday trading, indicating investor concerns about regulatory compliance and reputational risks [2] Group 2: Legal Proceedings - Berger Montague is investigating potential securities fraud claims against Hims & Hers, with a deadline for investors to seek lead plaintiff status by August 25, 2025 [1] - The investigation focuses on whether Hims & Hers and certain executives violated federal securities laws by providing false or misleading information to investors [3]

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial conditions during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Allegations and Financial Impact - The lawsuit claims that Elevance misled investors by stating they were monitoring cost trends related to Medicaid "redetermination" processes and that premium rates were sufficient to cover rising costs [4]. - Contrary to these claims, the redetermination process led to a significant increase in Medicaid member utilization, as healthier members were being removed from the program, which was not reflected in Elevance's financial guidance [5]. - On July 17, 2024, Elevance disclosed an expected increase in Medicaid utilization, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [6]. - Following a Q3 2024 earnings report on October 17, 2024, where Elevance missed EPS expectations by $1.33 (13.7%) due to elevated medical costs, the company lowered its EPS guidance for 2024 from $37.20 to $33.00 (11.3%), causing the stock price to decline by $52.61 per share, or 10.6%, to a closing price of $444.35 [7][8].

Core Viewpoint - Berger Montague is investigating potential securities law violations involving Petco Health and Wellness Company, Inc., following a class action lawsuit filed on behalf of investors who acquired Petco securities between January 14, 2021, and June 5, 2025 [1][2] Company Overview - Petco, headquartered in San Diego, CA, focuses on enhancing the lives of pets and pet parents [2] Allegations and Financial Impact - The complaint alleges that Petco made materially false and misleading statements regarding its pandemic-related tailwinds and the sustainability of its premium pet food business model [3] - It is claimed that the company overstated its ability to deliver profitable growth while downplaying operational challenges, leading to significant declines in Petco's stock price [3] - Notably, Petco's stock price dropped by more than 20% on August 24, 2023, following a downward revision of financial guidance, with further declines after subsequent disclosures and leadership changes [3]

Core Viewpoint - Hims & Hers Health Inc. is facing potential securities fraud claims following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and selling unapproved products [2][3]. Group 1: Company Actions and Allegations - Hims & Hers is under investigation for making materially false or misleading statements regarding its GLP-1 offerings and the partnership with Novo Nordisk [3]. - The company allegedly engaged in deceptive marketing practices and sold unapproved compounded versions of semaglutide, leading to significant investor concerns [2][3]. Group 2: Market Reaction - Following the announcement of the termination of the partnership with Novo Nordisk, shares of Hims & Hers experienced a decline of over 34% in intraday trading, indicating heightened investor anxiety regarding regulatory compliance and reputational risks [2]. Group 3: Legal Proceedings - Investors who purchased Hims & Hers securities between April 29, 2025, and June 22, 2025, are eligible to seek appointment as lead plaintiff representatives by the deadline of August 25, 2025 [1].

Core Viewpoint - A securities class action lawsuit has been filed against Compass Diversified Holdings for failing to disclose significant accounting irregularities related to its acquisition of Lugano Holdings, leading to a substantial drop in stock price [1][3][4]. Company Overview - Compass Diversified Holdings is a private equity firm headquartered in Westport, Connecticut, which acquired a majority interest in Lugano Holdings, Inc. in 2021 for an enterprise value of $256 million [2]. Lawsuit Details - The lawsuit claims that during the class period from May 1, 2024, to May 7, 2025, Compass did not disclose that Lugano violated accounting rules and that its 2024 financial results were distorted due to these irregularities [3]. - Compass is accused of failing to implement effective internal controls over its financial reporting [3]. Financial Impact - On May 7, 2025, Compass announced the identification of irregularities in Lugano's accounting practices, leading to the conclusion that the 2024 financial statements required restatement [4]. - Following this announcement, Compass' stock price fell by $10.70 per share, a decline of over 62%, closing at $6.55 on May 8, 2025 [4].

Core Viewpoint - A securities class action lawsuit has been filed against Compass Diversified Holdings for irregularities in financial reporting related to its acquisition of Lugano Holdings, leading to a significant drop in stock price [1][3]. Group 1: Company Overview - Compass Diversified Holdings is a private equity firm headquartered in Westport, Connecticut [2]. - In 2021, Compass acquired a majority interest in Lugano Holdings, Inc., a high-end jewelry designer, for an enterprise value of $256 million [2]. Group 2: Legal Developments - The class action lawsuit pertains to investors who purchased Compass securities between May 1, 2024, and May 7, 2025 [1]. - Investors have until July 8, 2025, to seek appointment as lead plaintiff in the class action [2]. - On May 7, 2025, Compass disclosed irregularities in Lugano's financing, accounting, and inventory practices, necessitating a restatement of previously issued financial statements for 2024 [3]. Group 3: Market Impact - Following the announcement of the financial irregularities, Compass' stock price fell by $10.70 per share, a decline of over 62%, closing at $6.55 on May 8, 2025 [3].

Core Viewpoint - Berger Montague is investigating potential securities law violations involving Petco Health and Wellness Company, Inc., following a class action lawsuit filed on behalf of investors who acquired Petco securities between January 14, 2021, and June 5, 2025 [1][2] Group 1: Legal Investigation - A class action lawsuit has been initiated against Petco, with a deadline for investors to seek lead plaintiff status by August 29, 2025 [2] - The lawsuit alleges that Petco made materially false and misleading statements regarding its pandemic-related growth and the sustainability of its premium pet food business model [3] Group 2: Financial Impact - The complaint claims that these misrepresentations led to significant declines in Petco's stock price, including a drop of over 20% on August 24, 2023, following a downward revision of financial guidance [3]